Everything below concerns Deamidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Linear tetrapeptide | Four residues joined by three peptide bonds |
| Sequence | Ala-Glu-Asp-Gly | Commonly abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free acid form |
| Monoisotopic mass | Approximately 390 Da | Matches values reported from mass spectrometry |
| Net charge near neutral pH | Negative | Contributed by glutamate and aspartate side chains |
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Essendon was fined $2 million, an Australian sporting record fine against a club. Essendon was ruled ineligible to compete in the 2013 AFL finals series, and would be relegated to finish ninth; (the club was on track to qualify for the finals in seventh place). Essendon was prohibited from exercising draft picks in two drafts: in 2013, its first and second-round draft picks were prohibited, and in 2014, it was prohibited from exercising the first and second-round draft picks it would have received based on its finishing position, but was granted the last draft pick in the first round. Senior coach James Hird was suspended from involvement in any football club for twelve months, effective 25 August 2013. Football operations manager Danny Corcoran was suspended from involvement in any football club for four months, with a further two-month suspended sentence, effective 1 October 2013. A fine of $30,000 was imposed on assistant coach Mark Thompson. Thompson personally paid $5,000 of the fine, with Essendon covering the balance. As part of the agreement, Hird dropped legal action that he had raised against the charges in the Supreme Court. Despite the connections between Essendon's AFL and VFL teams, the VFL team was still permitted to play in the VFL finals series. Club doctor Bruce Reid was also charged and issued a suspension. He announced he would contest the charges in the Supreme Court of Victoria, and on 18 September 2013, the AFL dropped the charges.
Many psychoactive drugs can be or have been specifically designed for sublingual administration, including barbiturates, benzodiazepines, opioid analgesics with poor gastrointestinal bioavailability, LSD blotters, coca leaves, some hallucinogens. This route of administration is activated when chewing some forms of smokeless tobacco (e.g. dipping tobacco, snus). intrarectal ("plugging"): administering into the rectum, most water-soluble drugs can be used this way. smoking (see also the section below): tobacco, cannabis, opium, crystal meth, phencyclidine, crack cocaine, and heroin (diamorphine as freebase) known as chasing the dragon. transdermal patches with prescription drugs: e.g. methylphenidate (Daytrana) and fentanyl. Many drugs are taken through various routes. Intravenous route is the most efficient, but also one of the most dangerous. Nasal, rectal, inhalation and smoking are safer. The oral route is one of the safest and most comfortable, but for some drugs has poorer bioavailability.
==== Syndiotactic polystyrene ==== Ziegler–Natta polymerization can produce an ordered syndiotactic polystyrene with the phenyl groups positioned on alternating sides of the hydrocarbon backbone. This form is highly crystalline with a Tm (melting point) of 270 °C (518 °F). Syndiotactic polystyrene resin is currently produced under the trade name XAREC by Idemitsu corporation, who use a metallocene catalyst for the polymerisation reaction.
Sources: en.wikipedia.org
== History == Founded in 1997 to produce contractual mods for state of the art 3D game engines, Black Widow Games would release 14 games between their first mod, Soldier Of Fortune (created for Rysher Entertainment), and 2003. Notable releases included the Half Life spin-off, USS Darkstar (produced for PC Gamer), and the They Hunger series (produced for PC Gamer). They Hunger in particular generated extensive player discussion and was considered an example of good gameplay within the realm of Half-Life mods. To promote the 2003 film Underworld, Sony Pictures commissioned Black Widow Games a promotional tie-in mod titled Underworld: Bloodline. The mod was available on Sony Pictures' official website until the end of 2007 and remains the only officially licensed Half-Life mod tied to a Hollywood film. In October 2005, the company declared it was not possible anymore to produce full-fledged single player mods working on low budget promotional projects within reduced development cycles, because of the higher level of detail required for modern 3D engines. At this time, the company revealed it had been secretly developing for almost a year its first commercial game They Hunger: Lost Souls, based on the Half-Life 2 Source engine, a successor to their popular Half-Life survival horror mod, They Hunger, which Black Widow Software had created in 1999 and released as a bonus with copies of the PC Gamer magazine. It would feature a plotline revolving around a zombie outbreak in northeastern Europe in the 1960s.
Big Drawer II (ビグドローワー2, Bigu Dorōwā Tsū): A chest-of-drawers-themed Super Kaijuki that he uses in his smear campaign against the Dekarangers before it is destroyed by Deka Base Robo. Abtrex (アブトレックス, Abutorekkusu): Abrella's personal Kaijuki that can assume the Abtrailer (アブトレーラー, Abutorērā) drill-vehicle mode. He tasks the Alienizer Angorl with using it to attack the Deka Base and damage Dekaranger Robo before the Kaijuki is destroyed by Deka Bike Robo and the Deka Wing Cannon. During the events of the crossover film Mahō Sentai Magiranger vs. Dekaranger, Agent X pilots the succeeding model, Abotrex (アボトレックス, Abotorekkusu), before it is blasted into space by Magi Legend and the Deka Wing Cannon and destroyed by Magi King, Dekaranger Robo, Travelion, and Deka Bike Robo. Abrella is voiced by Ryūsei Nakao (中尾 隆聖, Nakao Ryūsei).
==== Plans to sell TikTok's US operations ==== Since at least 2020, following calls to ban TikTok in the country, the Committee on Foreign Investment in the United States (CFIUS) has been investigating the company's 2017 merger with Musical.ly but has not finalized any of its negotiations with TikTok, such as the Project Texas proposal, waiting instead for Congress to act. In January 2025, Chinese officials began preliminary talks about potentially selling TikTok's US operations to Elon Musk if the app faced an impending ban due to national security concerns. While Beijing preferred TikTok remain under ByteDance's control, the sale could happen through a competitive process or with US government involvement. One possibility involved Musk's platform, X, taking over TikTok's US business. The move came ahead of a Supreme Court case that upheld the constitutionality of a law that would force a sale or ban of TikTok in the US by 19 January 2025, due to national security concerns regarding its ties to China. Other potential buyers included Project Liberty's "The People's Bid For TikTok" consortium of Frank McCourt with Kevin O'Leary, Steven Mnuchin, and Bobby Kotick, and an investor consortium led by Employer.com founder Jesse Tinsley that included Roblox CEO David Baszucki and YouTuber MrBeast and claimed to have secured over US$20 billion in commitments. The seriousness of these potential buyers was unclear. The day before the impending ban, California-based conversational search engine company Perplexity AI submitted a bid for a merger with TikTok US.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.
The compound came out of work on epithalamin, a peptide preparation derived from pineal tissue, conducted largely in Russian laboratories. Later studies in other countries examined it mainly in cell cultures and animal models.
The tetrapeptide sequence is a synthetic construct rather than a described circulating peptide. It was derived by analogy to peptide fractions obtained from tissue extracts, not isolated from blood or tissue as such.
The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.